Scholar Rock Announces FDA Approval of ISEMBYLD; Clarifies Post‑Market Study

What Happened
On September 14, 2026 Scholar Rock Holding Corp (SRRK) hosted an investor audio webcast announcing that the U.S. Food and Drug Administration approved ISEMBYLD™ (apitegromab‑mstn) to treat spinal muscular atrophy (SMA) in adults and children aged 2 and older who are receiving an SMN2‑targeted treatment. During the call, management mistakenly stated the FDA did not require bone or reproductive post‑marketing safety commitments. In an 8‑K filed September 15, 2026 (Regulation FD disclosure), the company corrected that the FDA did, in fact, outline a post‑marketing requirement and requests the company will comply with.

Key Details

• Investor Call: live audio webcast on September 14, 2026 announcing FDA approval of ISEMBYLD.
• Drug/Indication: ISEMBYLD™ (apitegromab‑mstn) approved for SMA in adults and children 2+ on SMN2‑targeted therapy.
• FDA post‑marketing requirements: establish a pregnancy safety study to collect/analyze pregnancy complications and birth outcomes for exposed pregnancies; separately, submit serious and non‑serious fracture cases as 15‑day “alert reports.”
• Company response: Scholar Rock intends to conduct the pregnancy study and submit fracture reports in compliance with the FDA’s request; the correction was disclosed under Item 7.01 (Regulation FD).

Why It Matters
An FDA approval is a major regulatory milestone that can enable commercialization and revenue opportunities. At the same time, required post‑marketing studies and expedited safety reporting can involve additional costs, data collection obligations and ongoing regulatory oversight. The 8‑K corrects the company’s prior public statement and confirms Scholar Rock will follow FDA requirements — important for investors monitoring regulatory risk, development timelines and potential post‑approval expenses.